710447Safer activatable, anti-EGFR bispecific antibodies for metastatic colorectal cancerClosedGRD Proof of ConceptInnovate UKShyDen Biotechnology is a start-up antibody drug discovery company based in the Open Innovation incubator, The Stevenage Bioscience Catalyst. It is discovering and developing the next generation of bispecific antibodies that can be switched on or off, thus carrying a new level of molecular regulation and thus safety. This project is to take two clinically-approved and established monoclonal antibodies and combine them in such a way as to produce a bispecific antibody when binding of one arm controls the other. This will be aimed at metastatic colorectal cancer, but later other solid cancers could be targeted.